FarmaMondo appointed by Amomed Pharma to exclusively Manage Access for Argipressin (Empressin®) for Russia and CIS region

FarmaMondo SA, the world’s leader in managing paid-access to unlicensed medicines, has been appointed by Amomed Pharma to exclusively distribute Empressin® via a Managed Access Program for targeted Healthcare Providers in Russia and CIS region.

FarmaMondo to manage access to Empressin for patients with septic shock in Russia, Belarus, Kazakhstan, Ukraine, Georgia, Armenia, Azerbaijan, Kyrgyzstan, Uzbekistan, Turkmenistan, Tadjikistan, Moldova.

Empressin has been approved in February 2015 by BfArM(Bundesinstitut für Arzneimittel und Medizinprodukte) for the treatment of catecholamine refractory hypotension following septic shock in patients older than 18 years. Under this program, Amomed will make Empressin (Argipressin) available in collaboration with FarmaMondo in response to unsolicited requests by oncologists and other clinical specialists on an individual named-patient basis in accordance with local and international regulations. Additional details can be obtained from FarmaMondo by contacting FarmaMondo.

Program Contact details

For all inquiries regarding Empressin®, please contact Empressin MAP – Program Manager

Marco Scicolone

Tel: +41 916976371,

Dr. Georgy Paroshin

Tel: +7 916 020 7310,

About FarmaMondo

FarmaMondo is a Swiss-based pharmaceutical company with a focus on providing paid access to unlicensed medicines. Our global footprint includes commercial operations in more than 70 markets, headquartered from Switzerland with regional hubs in Europe, Asia and Latin America.

For more information about FarmaMondo please visit

About Amomed Pharma

AMOMED PHARMA GmbH is an international, emerging and opportunity-driven specialty company based in Vienna, Austria. Since our establishment in 2006, we have grown into a renowned specialist for intensive care and emergency medicine, anesthesia and neuro-psychiatric products. Our goal is to position AMOMED as Europe’s leading player in anesthesia and intensive care medicine over the next few years.

For more information about Amomed Pharma please visit